| NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback |
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues. |
zacks.com |
2025-04-15 15:00:42 |
Czytaj oryginał (ang.) |
| What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? |
Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday. |
benzinga.com |
2025-04-14 14:49:19 |
Czytaj oryginał (ang.) |
| Structure Therapeutics CEO on latest GLP-1 developments |
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill. |
youtube.com |
2025-03-24 20:26:30 |
Czytaj oryginał (ang.) |
| Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate |
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. |
seekingalpha.com |
2025-03-20 11:28:26 |
Czytaj oryginał (ang.) |
| Why Structure Therapeutics Stock Was Stumbling This Week |
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment. |
fool.com |
2025-02-14 09:56:01 |
Czytaj oryginał (ang.) |
| Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences |
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. |
globenewswire.com |
2025-01-30 10:30:00 |
Czytaj oryginał (ang.) |
| Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst |
JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR. |
benzinga.com |
2025-01-06 16:53:01 |
Czytaj oryginał (ang.) |
| Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity |
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans |
globenewswire.com |
2024-12-17 18:01:00 |
Czytaj oryginał (ang.) |
| Structure CEO on the competitive landscape for oral GLP-1 drugs |
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings. |
youtube.com |
2024-12-05 20:17:59 |
Czytaj oryginał (ang.) |
| Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones |
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month. |
benzinga.com |
2024-11-19 16:10:39 |
Czytaj oryginał (ang.) |
| Structure Therapeutics to Participate in the Jefferies London Healthcare Conference |
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. |
globenewswire.com |
2024-11-15 10:30:00 |
Czytaj oryginał (ang.) |
| Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity |
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI |
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). |
globenewswire.com |
2024-11-05 04:00:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for October 23rd |
GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024. |
zacks.com |
2024-10-23 15:15:23 |
Czytaj oryginał (ang.) |
| Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients |
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024. |
seekingalpha.com |
2024-10-22 18:07:12 |
Czytaj oryginał (ang.) |
| Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? |
The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-10-09 14:56:25 |
Czytaj oryginał (ang.) |
| Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. |
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance. |
globenewswire.com |
2024-09-17 20:05:00 |
Czytaj oryginał (ang.) |
| Five Top Obesity Stocks to Buy and Hold Long Term |
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass. |
247wallst.com |
2024-09-12 15:50:00 |
Czytaj oryginał (ang.) |
| Structure Therapeutics Appoints Angus C. Russell to Board of Directors |
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry |
globenewswire.com |
2024-08-27 20:05:00 |
Czytaj oryginał (ang.) |
| Structure Therapeutics Announces Participation in Upcoming Investor Conferences |
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September: |
globenewswire.com |
2024-08-26 20:05:00 |
Czytaj oryginał (ang.) |
| Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say |
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday. |
marketwatch.com |
2024-08-26 16:00:00 |
Czytaj oryginał (ang.) |
| 3 Promising Biotech Stocks for the Long-Term: August 2024 |
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example. |
investorplace.com |
2024-08-13 18:00:44 |
Czytaj oryginał (ang.) |
| What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings? |
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release. |
zacks.com |
2024-07-24 13:56:22 |
Czytaj oryginał (ang.) |
| Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon. |
Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's. |
fool.com |
2024-07-22 13:20:00 |
Czytaj oryginał (ang.) |
| The 3 Most Undervalued Biotech Stocks to Buy in July 2024 |
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow. |
investorplace.com |
2024-07-12 10:08:00 |
Czytaj oryginał (ang.) |
| The 3 Smartest Biotech Stocks to Buy With $5K Right Now |
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE: LLY ). |
investorplace.com |
2024-06-28 14:09:51 |
Czytaj oryginał (ang.) |
| Could Structure Therapeutics Become the Next Novo Nordisk? |
Structure Therapeutics is developing a potentially powerful weight loss medicine. That medicine may end up being more effective than Novo Nordisk's offerings. |
fool.com |
2024-06-17 13:53:00 |
Czytaj oryginał (ang.) |